Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) (GABRA5)

The Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) is a critical component of a specific subtype of GABAA receptors primarily localized in the hippocampus and olfactory bulb [2, 6]. Unlike most GABAA receptors that facilitate rapid synaptic inhibition, α5-containing receptors are predominantly extrasynaptic and mediate tonic inhibition, which maintains a constant inhibitory tone and regulates the threshold for neuronal firing [4, 7]. This unique physiological role makes GABRA5 a key regulator of synaptic plasticity and cognitive functions such as learning and memory [1, 8]. Dysregulation of GABRA5 is strongly linked to cognitive deficits in Alzheimer's disease, schizophrenia, and Down syndrome, as well as neurodevelopmental disorders like autism [2, 15, 17]. Pharmacological strategies include the use of negative allosteric modulators (NAMs) to improve memory by reducing excessive tonic inhibition, and positive allosteric modulators (PAMs) for treating mood disorders [3, 5]. Additionally, GABRA5 has emerged as a potential target in oncology, specifically in MYC-amplified medulloblastoma, where its activation can selectively trigger cell death [16].

Other names

GABA(A) receptor subunit alpha-5Alpha-5 subunit of GABA-A receptorGABR alpha-5α5-GABA_A receptorGABA receptor alpha-5 subunit

Drugs targeting this receptor primarily act as allosteric modulators. Negative allosteric modulators (NAMs) or inverse agonists reduce the chloride ion influx mediated by GABA, thereby increasing neuronal excitability to enhance cognition [1, 5]. Positive allosteric modulators (PAMs) enhance the inhibitory effect of GABA, increasing chloride influx to provide anxiolytic or antidepressant effects [3, 6]. Some specific agonists can directly activate the receptor to induce membrane depolarization and apoptosis in certain cancer cells [16].